Short Interest in Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Drops By 77.9%

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totaling 670,614 shares, a decrease of 77.9% from the April 30th total of 3,038,967 shares. Based on an average daily volume of 2,410,748 shares, the short-interest ratio is presently 0.3 days. Currently, 6.4% of the company’s stock are sold short.

Hedge Funds Weigh In On Calidi Biotherapeutics

Hedge funds have recently made changes to their positions in the company. Warberg Asset Management LLC acquired a new position in shares of Calidi Biotherapeutics in the 3rd quarter valued at $28,000. Virtu Financial LLC acquired a new stake in Calidi Biotherapeutics during the 4th quarter worth about $25,000. Geode Capital Management LLC grew its position in Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after purchasing an additional 12,334 shares during the period. Finally, DRW Securities LLC acquired a new stake in Calidi Biotherapeutics during the 4th quarter worth about $173,000. 12.53% of the stock is owned by institutional investors and hedge funds.

Calidi Biotherapeutics Stock Performance

Shares of NYSEAMERICAN CLDI traded down $0.01 during mid-day trading on Friday, hitting $0.19. The stock had a trading volume of 1,508,070 shares, compared to its average volume of 2,278,589. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.92 and a current ratio of 1.92. The company has a 50 day moving average of $0.23 and a two-hundred day moving average of $0.78. Calidi Biotherapeutics has a twelve month low of $0.16 and a twelve month high of $19.20. The firm has a market cap of $3.57 million, a PE ratio of -0.04 and a beta of 1.38.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.